BioNTech SE (BNTX) Tops Q4 EPS, Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BNTX Hot Sheet
Join SI Premium – FREE
BioNTech SE (NASDAQ: BNTX) reported Q4 EPS of EUR9.26, EUR1.14 better than the analyst estimate of EUR8.12. Revenue for the quarter came in at EUR4.28 billion versus the consensus estimate of EUR3.78 billion.
GUIDANCE:
Estimated BioNTech COVID-19 vaccine revenues for the 2023 financial year is ~ EUR5 billion
For earnings history and earnings-related data on BioNTech SE (BNTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Superconductor (AMSC) Misses Q2 EPS by 2c ; Offers Guidance
- Cirrus Logic, Inc. (CRUS) Tops Q2 EPS by 27c; offers guidance
- Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
